DARA BioSciences (DARA) Reports Strong Results from KRN5500 in Neuropathic Pain
Tweet
Share
E-mailGet Alerts DARA Hot Sheet
Join SI Premium – FREE
DARA BioSciences, Inc. (Nasdaq: DARA) announced today that the Company has been selected to present the positive clinical data results for KRN5500, its lead compound for Neuropathic Pain, at the 5th Annual Therapeutics Summit to be held September 20-21, 2011 in San Francisco.
Results were presented from analyses of a recently completed randomized, double-blind, placebo-controlled, dose escalation study designed to evaluate safety and efficacy of a novel spicamycin derivative, KRN5500, in patients with advanced cancer experiencing neuropathic pain. Placebo response in these types of studies often dilutes the ability to detect potential drug effects. The presentation will explore the ramifications of placebo response in randomized, controlled trials for analgesia.
It is common that patients respond to the placebo in pain trials where subjective outcome data are collected. Patients want to feel better. The placebo effect is a normal physiological event and can be as high as 40% to 50%, requiring an even higher drug effect to show a difference. The placebo response can be thought of as background noise, and what researchers look for is a clinical benefit over and above what is in that background. Researchers are often faced with a dilemma: Is the drug a failure or is the placebo response too great to see the drug response? Often clinical trials must be quite large in order to detect the potential benefit of active treatment over placebo. Although this particular trial had only 19 patients, it had a low placebo response, enabling the positive KRN5500 results to be more easily interpreted.
Results were presented from analyses of a recently completed randomized, double-blind, placebo-controlled, dose escalation study designed to evaluate safety and efficacy of a novel spicamycin derivative, KRN5500, in patients with advanced cancer experiencing neuropathic pain. Placebo response in these types of studies often dilutes the ability to detect potential drug effects. The presentation will explore the ramifications of placebo response in randomized, controlled trials for analgesia.
It is common that patients respond to the placebo in pain trials where subjective outcome data are collected. Patients want to feel better. The placebo effect is a normal physiological event and can be as high as 40% to 50%, requiring an even higher drug effect to show a difference. The placebo response can be thought of as background noise, and what researchers look for is a clinical benefit over and above what is in that background. Researchers are often faced with a dilemma: Is the drug a failure or is the placebo response too great to see the drug response? Often clinical trials must be quite large in order to detect the potential benefit of active treatment over placebo. Although this particular trial had only 19 patients, it had a low placebo response, enabling the positive KRN5500 results to be more easily interpreted.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
- Mangoceuticals (MGRX) Acquires Global Preventive Care Patent Portfolio
- XOMA (XOMA) Earns $9M Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
